| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.0001 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.0001 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.0002 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.18 | 0.0002 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.0002 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0006 |
| mRNA | KHS101 | CTRPv2 | pan-cancer | AAC | -0.16 | 0.0007 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0007 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0008 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.0009 |